[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567661":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":24,"locations":29,"responsibleParty":73,"collaborators":23,"id":75,"slug":23,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":23,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":23,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":32,"whyStopped":23,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Tune Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tune-401 Part I : Single Ascending Dose","EXPERIMENTAL","Epigenetic gene silencing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration",[13],"Genetic: Tune-401",{"label":15,"type":10,"description":11,"interventionNames":16},"Tune-401 Part II :Single\u002FFinite Multiple Dose",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"GENETIC","Tune-401","Epigenetic gene silencing therapy",[9,15],null,[25],{"name":5,"role":26,"phone":27,"phoneExt":23,"email":28},"CONTACT","855 755 8863","clinical.operations@tunetx.com",[30,46,59],{"facility":31,"status":32,"city":33,"state":23,"zip":23,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Queen Mary Hospital, University of Hong Kong","RECRUITING","Hong Kong",{"type":35,"coordinates":36},"Point",[37,38],114.17469,22.27832,{"lat":38,"lon":37},[41,43],{"name":42,"role":26,"phone":23,"phoneExt":23,"email":23},"Man Fung Yuen",{"name":44,"role":45,"phone":23,"phoneExt":23,"email":23},"Man Fung Yuen, MD","PRINCIPAL_INVESTIGATOR",{"facility":47,"status":32,"city":48,"state":23,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"PMSI Republican Clinical Hospital \"Timofei Mosneaga\", Arensia Exploratory Medicine Phase I Unit","Chisinau","MD2025","Moldova",{"type":35,"coordinates":52},[53,54],28.85938,47.00902,{"lat":54,"lon":53},[57],{"name":58,"role":45,"phone":23,"phoneExt":23,"email":23},"Alina Jucov",{"facility":60,"status":32,"city":61,"state":23,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"New Zealand Clinical Research","Auckland","1010","New Zealand",{"type":35,"coordinates":65},[66,67],174.76349,-36.84853,{"lat":67,"lon":66},[70],{"name":60,"role":26,"phone":71,"phoneExt":23,"email":72},"+64 9 373 3474","Rhythm.Auckland@nzcr.co.nz",{"type":74,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100567661",false,"NCT06671093","Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B","Phase 1b Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tune-401 in Participants With Chronic Hepatitis B Infection","Inclusion Criteria:\n\n* M\u002FF, BMI ≥ 18.5 kg\u002Fm² at screening, age 18-75, inclusive\n* Diagnosed with Chronic Hepatitis B\n* On nucleos(t)ide analogue\n* HBeAg-negative or positive\n\nExclusion Criteria:\n\n* ALT\u002F AST ≥ 1.5 × upper limit of normal (ULN) and total bilirubin ≥ 1. 5 × ULN\n* Participants with any evidence or history of liver disease of non-HBV etiology\n* Other protocol defined Inclusion\u002FExclusion criteria may apply","ALL","18 Years","75 Years",{"count":85,"type":86},36,"ESTIMATED","INTERVENTIONAL",[89],"PHASE1","This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.",[92,93,94,95],"Chronic Hep B","Chronic Hepatitis b","Chronic Hepatitis","HBV",[20,97,98],"Tune-401-001","CHB","2026-01-02",{"date":101,"type":102},"2026-01-06","ACTUAL",{"date":104,"type":102},"2024-11-29",{"date":106,"type":86},"2028-10-30",{"name":5,"class":6},3]